Q2 FY27 net profit up 4.15%, H1 FY27 net profit up 20.52%

Ebitda Margin CompressionResults RestatedResults View source PDF Explain this filing

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.0%Reaction day

₹558.05

prior close

₹547.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-9.6% vs market

Pharmaceuticals peers, median of 171sector+0.4%-9.3% vs sector

On the reaction day the stock moved 9.6 pts less than Nifty Microcap 250 and 9.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-6.4

10m

-5.4

15m

-6.2

30m

-5.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.0+0.7-9.6+0.4-9.3

Next day

-10.8pendingpending-0.6-10.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited standalone and consolidated Q2 and H1 FY27 results, with a clean limited review. Q2 revenue was Rs 191.35 crore, total income Rs 200.88 crore (up 17.75%) and net profit Rs 20.84 crore (up 4.15%). H1 net profit rose 20.52% to Rs 57.50 crore, total income rose 18.39% to Rs 402.43 crore and EBITDA rose 18.37% to Rs 84.92 crore. The company is net debt free and targets Rs 1,000 crore revenue in three years.

Likely market impact

H1 net profit rose 20.5%, but slow Q2 profit growth and weaker Q2 margins may limit gains; debt-free balance sheet supports confidence.